Preliminary exploration of perioperative immunotherapy for locally advanced gastric cancer

Ding Xuewei; Liang Han

doi:10.3969/j.issn.1003-5591.2024.02.001

您当前的位置：

首页 >

文章列表页 >

Preliminary exploration of perioperative immunotherapy for locally advanced gastric cancer

更新时间：2026-11-05

- Preliminary exploration of perioperative immunotherapy for locally advanced gastric cancer
- J Abdominal Surg Vol. 37, Issue 2, Pages: 81-85(2024)
- 作者机构：
  
  天津医科大学肿瘤医院胃部肿瘤科国家恶性肿瘤临床医学研究中心天津市恶性肿瘤临床医学研究中心天津市消化系统肿瘤重点实验室，天津 300060
- 作者简介：
  
  Liang Han， Email： tjlianghan@126.com
- 基金信息：
- DOI：10.3969/j.issn.1003-5591.2024.02.001
  CLC： R656.6
- Received：15 March 2024，
  
  Published：22 April 2024
- 稿件说明：
移动端阅览
丁学伟,梁寒.免疫治疗在局部进展期胃癌围手术期治疗的初步探索[J].腹部外科,2024,37(02):81-85.

Ding Xuewei,Liang Han.Preliminary exploration of perioperative immunotherapy for locally advanced gastric cancer[J].J Abdominal Surg,2024,37(02):81-85.
丁学伟,梁寒.免疫治疗在局部进展期胃癌围手术期治疗的初步探索[J].腹部外科,2024,37(02):81-85. DOI： 10.3969/j.issn.1003-5591.2024.02.001.

Ding Xuewei,Liang Han.Preliminary exploration of perioperative immunotherapy for locally advanced gastric cancer[J].J Abdominal Surg,2024,37(02):81-85. DOI： 10.3969/j.issn.1003-5591.2024.02.001.

摘要

基于Resolve试验和FLOT4试验的结果，胃癌新辅助化疗+D2根治术成为当前标准治疗策略之一。程序性细胞死亡蛋白1/程序性细胞死亡蛋白1配体1单抗为代表的免疫疗法显著改善了晚期胃癌病人的生存结局。近年来多项胃癌围手术期化疗+免疫治疗的研究显示，化疗+免疫治疗显著提高了病理完全缓解率。MATTERHONE研究的近期疗效较为显著，但是ATTRACTION-5和KEYNOTE-585研究未达到预期。免疫优势人群的筛选和化疗方案的选择是围手术期免疫治疗的主要问题。

Abstract

Based upon the findings of Resolve and FLOT4 trials， neoadjuvant chemotherapy + D2 radical resection for gastric cancer has become one of the latest standard treatments. Immunotherapy of PD-1/PD-L1 monoclonal antibody has significantly improved the survival outcomes of patients with locally advanced gastric cancer. Perioperative chemoimmunotherapy could significantly boost the pathological complete response rate. The Matterhorn study has demonstrated significant short-term efficacy. However， the ATTRACTION-5 and KEYNOTE-585 studies failed to fulfill the expectations. Screening of immunodominant populations and a proper choice of chemotherapeutic regimen are two major issues of perioperative immunotherapy.

关键词

Keywords

references

Freddie Bray ， Mathieu Laversanne ， Hyuna Sung ， et al . Global cancer statistics 2022： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA Cancer J Clin ，2024 Apr 4 . DOI： 10.3322/caac.21834 http://dx.doi.org/10.3322/caac.21834 . https：//gco.iarc.who.int/today https://gco.iarc.who.int/today ， accessed.

Zeng HM ， Ran XH ， An L ， et al . Disparities in stage at diagnosis for five common cancers in China：a multicentre，hospital-based，observational study ［J］. Lancet Public Health ， 2021 ， 6 （ 12 ）： e877 - e887 . DOI： 10.1016/S2468-2667（21）00157-2 http://dx.doi.org/10.1016/S2468-2667（21）00157-2 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）胃癌临床诊疗指南2023 ［M］. 北京：人民卫生出版社， 2023 ： 68 - 71 .

National ComprehesiveCancer Network . Gastric Cancer 2024V1 ［M］. 47 .

Terashima M ， Kang YK ， Kim YW ， et al . ATTRACTION-5：a phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage Ⅲ （pStage Ⅲ） gastric or gastroesophageal junction （G/GEJ） cancer ［J］. J Clin Oncol ， 2023 ， 41 （ 16_suppl ）： 4000 . DOI： 10.1200/jco.2023.41.16_suppl.4000 http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4000 .

Zhang XT ， Liang H ， Li ZY ， et al . Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy （RESOLVE）：an open-label，superiority and non-inferiority，phase 3 randomised controlled trial ［J］. Lancet Oncol ， 2021 ， 22 （ 8 ）： 1081 - 1092 . DOI： 10.1016/S1470-2045（21）00297-7 http://dx.doi.org/10.1016/S1470-2045（21）00297-7 .

Oh DY ， Janjigian YY ， Al-Batran SE ， et al . 129O Pathological complete response （pCR） to durvalumab plus 5-fluorouracil，leucovorin，oxaliplatin and docetaxel （FLOT） in resectable gastric and gastroesophageal junction cancer （GC/GEJC）：Interim results of the global，phase Ⅲ MATTERHORN study ［J］. Ann Oncol ， 2023 ， 34 ： S1520 - S1521 . DOI： 10.1016/j.annonc.2023.10.265 http://dx.doi.org/10.1016/j.annonc.2023.10.265 .

Shitara K ， Rha SY ， Wyrwicz LS ， et al . LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer：The phase Ⅲ KEYNOTE-585 study ［J］. Ann Oncol ， 2023 ， 34 ： S1316 . DOI： 10.1016/j.annonc.2023.10.075 http://dx.doi.org/10.1016/j.annonc.2023.10.075 .

Xuewei Ding . Perioperative sintilimab combination with SOX for resectable locally advanced gastric/gastroesophageal junction cancer（GC/GEJC）： Initial findings of asingle-arm phase II trial . J Clin Oncol 40 ， 2022 （suppl 4； abstr 1）：72S.

Yuping Yin ， Yao Lin ， Kaixiong Tao ， et al . Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil （S-1） plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer： Early results of a phase 2， single-arm trial ［J］. Front Oncol ， 2022 ， 12 ： 959295 . DOI： 10.3389/fonc.2022.959295 http://dx.doi.org/10.3389/fonc.2022.959295 .

Honghai Guo ， Ping’an Ding ， Qun Zhao ， et al . Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer： A single-arm， open-label， phase Ⅱ trial ［J］. Front Oncol ， 2022 ， 12 ： 927781 . DOI： 10.3389/fonc.2022.927781 http://dx.doi.org/10.3389/fonc.2022.927781 .

Tang ZQ ， Wang Y ， Liu D ， et al . The Neo-PLANET phase Ⅱ trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction ［J］. Nat Commun ， 2022 ， 13 （ 1 ）： 6807 . DOI： 10.1038/s41467-022-34403-5 http://dx.doi.org/10.1038/s41467-022-34403-5 .

Ding XW ， Wang XJ ， Li B ， et al . PERSIST：a multicenter，randomized phase Ⅱ trial of perioperative oxaliplatin and S-1 （SOX） with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer （GC/GEJC）［J］. J Clin Oncol ， 2023 ， 41 （ 4_suppl ）： 364 . DOI： 10.1200/jco.2023.41.4_suppl.364 http://dx.doi.org/10.1200/jco.2023.41.4_suppl.364 .

Yuan SQ ， Nie RC ， Jin Y ， et al . Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer： a randomized phase 2 trial ［J］. Nat Med ， 2024 ， 30 （ 2 ）： 552 - 559 . DOI： 10.1038/s41591-023-02721-w http://dx.doi.org/10.1038/s41591-023-02721-w .

Thierry Andre ， David Tougeron ， Guillaume Piessen ， et al . Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma： The GERCOR NEONIPIGA Phase Ⅱ Study ［J］. J Clin Oncol ， 2023 ， 41 （ 2 ）： 255 - 265 . DOI： 10.1200/JCO.22.00686 http://dx.doi.org/10.1200/JCO.22.00686 .

Filippo Pietrantonio . INFINITY： A multicentre， single-arm， multi-cohort， phase Ⅱ trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high （MSI） resectable gastric or gastroesophageal junction adenocarcinoma （GAC/GEJAC）［J］. J Clin Oncol ， 2023 ，（suppl 4； abstr 1）. 89 S.

Ning Li . Phase Ⅱ study of SHR1210 and trastuzumab in combination with CAPOX forneoadjuvant treatment of HER2-positive gastric or gastroesophageal junction（GEJ） adenocarcinoma ［J］. J Clin Oncol ， 2022 ，（suppl 4； abstr 1）. 296 .

Wang F ， Zhao C ， Xia J ， et al . 1539P Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer （GC/EGJC）：Preliminary results of a phase II，single-arm trial ［J］. Ann Oncol ， 2023 ， 34 ： S865 . DOI： 10.1016/j.annonc.2023.09.1451 http://dx.doi.org/10.1016/j.annonc.2023.09.1451 .

中国抗癌协会胃癌专业委员会 . 基于PD-L1 蛋白表达水平胃癌免疫治疗专家共识（2023 版）［J］中国肿瘤临床， 2024 ， 1 ， 25 . DOI： 10.12354/j.issn.1000-8179.2023.20231335 http://dx.doi.org/10.12354/j.issn.1000-8179.2023.20231335 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

局部进展期胃癌新辅助化疗联合免疫治疗术后复发模式及预后

Current status and recent advances in the application of mini-invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer

Research advances of immunotherapy for gastric cancer

Current status and future prospects of tumor-associated macrophages and PD-1/PD-L1 in gastric cancer immunotherapy

Progress and clinical decision-making in perioperative immunotherapy for locally advanced gastric cancer

Related Author

Yin Yuping

Sun Xiong

Ding Jianing

Li Tianhao

Wu Ke

Liu Ke

Li Anshu

Shuai Xiaoming

Related Institution

Department of General Surgery， First Medical Center， Chinese PLA General Hospital

School of Medicine， Nankai University

Department of Gastrointestinal Surgery， Affiliated Jingzhou Hospital， Yangtze University

Department of General Surgery， Third Hospital of Shanxi Medical University， Shanxi Bethune Hospital， Shanxi Academy of Medical Sciences， Tongji Shanxi Hospital

AI问答

⁰